Memantine or Riluzole Prophylaxis for Corticosteroid-induced Mood and Declarative Memory Changes

• Status: Terminated
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose is to determine if patients scheduled to receive prescription corticosteroid therapy for inflammatory illnesses who are given either memantine or riluzole pretreatment will show lesser declarative memory impairment than those receiving placebo.

The exploratory purpose is to determine if patients scheduled to receive prescription corticosteroid therapy for inflammatory illnesses who are given memantine or riluzole pretreatment will show a smaller increase in manic/hypomanic symptom severity than those receiving placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Texas Southwestern Medical Center
• Treatments: Memantine; Riluzole

Criteria

Inclusion Criteria:

• 18-70 years old

• English speaking

• Able to provide informed consent

• Scheduled to receive a corticosteroid burst of at least 20 mg prednisone or equivalent for at least 7 days

Exclusion Criteria:

• History of allergic reaction to memantine and/or riluzole

• Pregnant or nursing women

• History of liver disease, myocardial infarction, renal failure, diabetes with poor glycemic control, or other unstable medical condition

• Mental retardation, dementia, or other severe cognitive disorder

• Prior prednisone therapy in the last 14 days

• Current alcohol/substance abuse/dependence